Trace analysis of therapeutic inertia and subsequent hemoglobin A1c outcomes in a 2-year cohort study

Huang, L-YL-YHuangChen, T-TT-TChenMING-CHIN YANGShau, W-YW-YShauSu, SSSuLai, M-SM-SLai2022-01-072022-01-0720211128-3602https://scholars.lib.ntu.edu.tw/handle/123456789/591883Our understanding of therapeutic inertia in diabetes care is incomplete in terms of an assessment across a nationwide population. The key objectives of this investigation were to measure therapeutic inertia and link this phenomenon to the important surrogate outcome of hemoglobin A1c (HbA1c) control in a nationwide cohort.enTherapeutic inertia; Intensified therapy; HbA1c; Diabetes mellitus; CLINICAL INERTIA; DIABETES-MELLITUS; PREVALENCE; PEOPLE[SDGs]SDG3acarbose; buformin; chlorpropamide; glibenclamide; gliclazide; glimepiride; gliquidone; hemoglobin A1c; insulin; metformin; nateglinide; pioglitazone; repaglinide; rosiglitazone; sulfonamide; sulfonylurea derivative; tolazamide; antidiabetic agent; glycosTrace analysis of therapeutic inertia and subsequent hemoglobin A1c outcomes in a 2-year cohort studyjournal article10.26355/eurrev_202105_25832340028242-s2.0-85106621827WOS:000649036200016https://api.elsevier.com/content/abstract/scopus_id/85106621827https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106621827&doi=10.26355%2feurrev_202105_25832&partnerID=40&md5=eff9cf2af5fa14c534a780d68e6b10a8